elocta® 2000 iu 2000 iu/vial injection
gulf drug llc dubai-street no 10 - efmoroctocog alfa - injection - 2000 iu/vial - n/a-n/a
elocta® 2000 iu
efmoroctocog alfa ( recombinant coagulation factor viii ) -
elocta 3000 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 3000 iu
elocta 250 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 250 iu
elocta 2000 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 2000 iu
elocta 1500 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 1500 iu
elocta 1000 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 1000 iu
elocta 500 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 500 iu
eloctate (antihemophilic factor- recombinant, fc fusion protein kit
bioverativ therapeutics inc. - efmoroctocog alfa (unii: 7pcm518ylr) (efmoroctocog alfa - unii:7pcm518ylr) - (1-743)-(1638-2332)-blood-coagulation factor viii (synthetic human) fusion protein with immunoglobulin g1 (synthetic human fc domain fragment), (1444-6'),(1447-9')-bis(disulfide) with immunoglobulin g1 (synthetic human fc domain fragment) 250 [iu] in 3 ml - eloctate, antihemophilic factor (recombinant), fc fusion protein, is a recombinant dna derived, antihemophilic factor indicated in adults and children with hemophilia a (congenital factor viii deficiency) for: - on-demand treatment and control of bleeding episodes, - perioperative management of bleeding, - routine prophylaxis to reduce the frequency of bleeding episodes. limitation of use eloctate is not indicated for the treatment of von willebrand disease. eloctate is contraindicated in patients who have had life-threatening hypersensitivity reactions to eloctate or its excipients (sucrose, sodium chloride, l-histidine, calcium chloride and polysorbate 20). risk summary there are no studies of eloctate use in pregnant women to inform a drug-associated risk. the background risk of major birth defects and miscarriage in the indicated population is unknown; however, the background risk of major birth defects in the u.s. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnanci
elocta 250 ui 1 vial + 1 xeringa precarregada